Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Walnut Creek, California, United States, 94598
- Diablo Clinical Research
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Kentucky Clinical Trials Laboratory
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subjects (or their legal representative) who are willing to voluntarily consent to the study
Exclusion Criteria:
- There are no exclusion criteria
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose (mg/dL) levels
Time Frame: Patient's blood is tested within 3 minutes of blood collection
|
Data analysis
|
Patient's blood is tested within 3 minutes of blood collection
|
|
Hematocrit (%PCV) levels
Time Frame: Patient's blood is tested within 3 minutes of blood collection
|
Data analysis
|
Patient's blood is tested within 3 minutes of blood collection
|
|
Sodium (mmol/L) levels
Time Frame: Patient's blood is tested within 3 minutes of blood collection
|
Data analysis
|
Patient's blood is tested within 3 minutes of blood collection
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Chris P Edwards, BSc, Abbott Point of Care
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CS-2016-0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In-vitro
-
NCT07642297Not yet recruitingDiffuse Cutaneous Systemic Sclerosis | Skin Fibrosis | Systemic Sclerosis (SSc)
-
NCT06575231Completed
-
NCT05199740RecruitingMitochondrial Myopathies
-
NCT06077734TerminatedMuscle Weakness | Stem Cell Transplantation | Sarcopenia | Cachexia | Mesenchymal Stem Cells | Atrophy, Muscle